Novo Holdings led a €90m Series A funding in Orbis Medicines.

Novo Holdings, a Novo Nordisk Foundation's wholly owned holding company, led a €90m Series A funding in Orbis Medicines, a macrocycle drug discovery company, with participation from New Enterprise Associates, Eli Lilly and Company, Cormorant, Export and Investment Fund of Denmark and Forbion. “The benefits of an oral format include dose control, convenience, ease of dosing, and feasibility for much larger populations of patients. Orbis is leveraging macrocycles to unlock these benefits in major areas validated by existing biologics, and we are proud to have played an integral role in shaping the company from its earliest stages. The combination of automated chemical synthesis, high-throughput assays, and machine learning ignited our enthusiasm and drove us to start collaborating to build Orbis before its first financing round. We congratulate Morten on his appointment and the team on their successes to-date and look forward to advancing the future of macrocycles,” João Ribas, Novo Holdings Principal.